Compare Revvity Inc (RVTY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Smith & Nephew plc — how do they compare? Revvity Inc trades at $110.7 (market cap $11.87B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Revvity Inc and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| RVTY | SNN | |
|---|---|---|
Market Cap | $11.87B | $12.64B |
Sector | Technology | Health |
52-Week High | $117.75 | $38.70 |
52-Week Low | $82.26 | $28.73 |
Enterprise Value | $14.36B | $15.41B |
Dividend Yield | 0.26% | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
